Medsearch Institute
- Address
- ul. Dworcowa 8, 88-181 Jaksice, Poland
Cardiovascular Disease Research
The Medsearch Institute is advancing care for cardiovascular diseases by evaluating strategies that lower cardiovascular risk, improve blood‑pressure control, and protect against heart‑related events.
- Allopurinol as a preventive therapy for high‑risk patients
- Triple single‑pill combination (SPC) regimens for resistant hypertension
- Comparison of eplerenone, spironolactone and torasemide on blood‑pressure reduction
- Management approaches for ischemic stroke, intracerebral haemorrhage and TIA
- Therapeutic options for peripheral arterial disease and atrial fibrillation
Ongoing trials aim to demonstrate safer, more effective treatments that can be integrated into everyday practice for patients in Jaksice and beyond.
Male Urogenital Health Studies
Research at the site explores solutions for erectile dysfunction, including tools that help patients decide safely about using sildenafil.
- Self‑assessment diagnostic tool for appropriate sildenafil use
- Patient‑reported outcomes on sexual function and quality of life
- Impact of comorbid conditions such as hypertension on erectile health
The goal is to empower men to manage their condition with confidence while minimizing risks.
Respiratory Research Initiatives
The institute conducts studies on respiratory tract diseases targeting conditions like asthma and COPD, as well as acute upper‑airway infections that do not require antibiotics.
- Statin therapy to reduce COPD exacerbations in smokers
- Equivalence and superiority trials of inhaled fluticasone furoate/vilanterol combinations
- Effectiveness of Actisoufre nasal spray for acute rhinitis, rhinopharyngitis and rhinosinusitis
- Biomarker‑guided approaches to improve asthma control
These efforts aim to enhance symptom management, reduce flare‑ups, and provide better therapeutic options for patients across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Agencja Badań Medycznych2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medsearch Institute
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, prospective clinical TRrial evaluating patient’s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction. TRUST Trial on Responsible Use and Self-assessed Treatment. | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Phase III | Not Recruiting | Feb 2026 | Apr 2026 |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allopurinol | 1 | Unknown | 2024-03-28 | 2024-03-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.